

AD_____

Award Number: W81XWH-04-1-0046

TITLE: Identify the Impact of TGF- β Signaling on the Stroma in the Progression of Prostate Cancer

PRINCIPAL INVESTIGATOR: Neil A. Bhowmick, Ph.D.

CONTRACTING ORGANIZATION: Vanderbilt University
Nashville, TN 37232-6838

REPORT DATE: March 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-03-2007		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 MAR 2006 - 28 FEB 2007	
4. TITLE AND SUBTITLE Identify the Impact of TGF- β Signaling on the Stroma in the Progression of Prostate Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0046	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Neil A. Bhowmick, Ph.D. E-Mail: neil.bhowmick@vanderbilt.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Vanderbilt University Nashville, TN 37232-6838				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT As a result of androgen ablation TGF- β 1 expression levels transiently elevate and regression of benign prostate hyperplasia as well as prostate cancer cells for the most part occur. Better understanding of prostate androgen responsiveness is critical in understanding and ultimately combating androgen-non-responsive prostate cancer. Studying the conditional TGF- β type II receptor fibroblast knockout mouse model we developed (Tgfr2fspko), we found that TGF- β signaling in the prostate stromal fibroblasts regulate both stromal and epithelial differentiation in the prostate. Notably the data dispels previous reports that TGF- β signaling is required for myofibroblast differentiation. As proposed we attempted to develop mice that are stromally knocked out for TGF- β signaling and express the large T antigen in the prostate epithelia, but was unsuccessful. We have however acquired techniques in our laboratory to perform tissue recombination experiments where the identical cell types (prostate stroma and epithelia) can generate prostate glands through xenografting, that display similar phenotypic characteristics of intact mice. We hope to gain permission to progress with these experiments in order to address the mechanism of stromal TGF- β signaling impact on prostate cancer androgen responsiveness.					
15. SUBJECT TERMS No subject terms provided.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	11	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Introduction	1
Body	2
Key Research Accomplishments	6
Reportable Outcomes	7
Conclusions	7
References	8

a. Introduction

The prostate epithelial and stromal compartments interact to regulate prostate development and function, in part through the tight regulation of glandular apoptosis and proliferation. These interactions are mediated by various factors that include hormones and cytokines. Specific signaling by androgens is required for prostate development and maintenance of function through the stimulation of proliferation and inhibition of apoptosis of prostatic epithelial cells (Hayward and Cunha, 2000; Montgomery et al., 2001). Cytokines such as EGF, IGF, and TGF- β isoforms can also in-turn stimulate the expression of the androgen receptor (AR) in an androgen-independent fashion (Byrne et al., 1996; Culig et al., 1996). Often the development and progression of prostate cancer is dependent on androgens and their receptor for prostate cellular proliferation and differentiation. As a result, its inhibition has been the primary therapy for metastatic prostate cancer and much effort has been devoted to elucidating the role of the androgen receptor in prostate cancer. As a result of androgen ablation, TGF- β 1 expression levels transiently elevate and regression of benign prostate hyperplasia as well as prostate cancer cells for the most part occur. Better understanding of prostate androgen responsiveness is critical since androgen-signaling antagonists are currently used in treating patients with malignant prostate cancer, benign prostate hyperplasia, and as a chemoprevention of prostate cancer in clinical trials. However, populations of hormone-non-responsive cancer cells unfortunately frequently arise. The central hypothesis of this proposal is that TGF- β signaling in the prostatic fibroblasts contributes to normal prostatic epithelial differentiation; when this signal is altered in the case of some cancers the differentiation status of the epithelia is altered.

TGF- β isoforms (TGF- β 1, β 2, β 3) have long been established as physiological regulators of prostate growth because of their ability to inhibit cell proliferation and mediate apoptosis (Kyprianou and Isaacs, 1989; Martikainen et al., 1990). TGF- β s exert their effects through binding to the TGF- β type II receptor (T β RII) and subsequent recruitment of the type I receptor (T β RI) for downstream cytoplasmic signaling through multiple parallel signaling pathways (Attisano and Wrana, 2002). TGF- β plays a key role in the steroidal regulation of tissues and in the important growth regulation axis existing between androgenic signaling, smooth muscle differentiation and epithelial proliferation. The present proposal seeks to address the role of TGF- β signaling in mouse prostate tissue under in vivo conditions in light of signaling pathways identified through studies in cell lines. In order to understand the role of TGF- β in the prostate we have developed and studied mouse models, that employ the Cre-lox methodology to conditionally ablate T β RII expression in the stromal fibroblasts (Bhowmick et al., 2004) and those that express the large SV40 T antigen transgene (TAG) in the prostate epithelia (from collaborator, Dr. Robert Matusik, Vanderbilt U., TN) (Kasper et al., 1998). The proposal was based on preliminary data that ablation of T β RII in fibroblasts results in preneoplastic prostate intraepithelial neoplasia (PIN) lesions and prostate-specific TAG expression results in PIN and progression of focal adenocarcinoma (Kasper et al., 1998). We proposed to develop mice that expressed both TAG in the prostate epithelia and concomitant loss of T β RII in the stromal fibroblasts (mouse model termed TNT) to examine epithelial and stromal differentiation (Task1). Since these TNT mice were not thought not to be able to live past 8 weeks of age, we also proposed to rescue the prostatic tissues from these mice as xenografts and further study differences in cellular differentiation and androgen responsiveness (Task2).

In the last annual report, we described the importance of Wnt signaling in the prostatic epithelia to support its androgen independent survival. In summary, we found that the loss of TGF- β responsiveness of the prostatic stroma resulted in the upregulation of Wnt ligand expression that mediated paracrine signaling in the epithelial compartment. We have furthered these findings at the clinical and mechanistic level in the past year.

b. Body

Human prostate cancer is associated with the loss of the TGF- β type II receptor expression the stromal compartment

We wanted to take a closer look at the stromal compartment for the expression of TGF- β type II receptor (T β RII) in human prostate tissues. Immunohistochemistry of 59 patient tissues suggested majority of benign prostate epithelia and stroma was in fact positive for T β RII expression (**Figure 1**). However in both Gleason 7 and 9 tumors examined most of the cancer associated stromal cells were devoid of T β RII expression. Interestingly, most of the epithelia in all tissues examined were highly positive for histochemical staining. In the past, the loss of the TGF- β receptor has been only reported in the epithelial compartment of highly aggressive prostate cancer. We are still looking into acquiring more cancer, benign, as well as PIN tissue to further support these findings. This result provides support to the mouse model we developed earlier, that had a loss of T β RII expression in the stromal compartment developing PIN lesions (Tgfr2^{fspKO}).




Figure 1.
Immunohisto-
chemistry for
the expression
of T β RII.
Specific
attention was
given to T β RII
expression
(brown) in the
stromal
compartment in
the prostatic
tissues. All
sections were
nuclear
counterstained
with
hematoxylin
(blue).

The loss of TGF- β type II receptor expression in the prostatic stroma can lead to adenocarcinoma in mice

The Tgfr2^{fspKO} mice are generally frail mice that die by 6 weeks of age. The short age of the mice did not allow for us to observe the progression of the prostatic phenotype. However, through the subrenal grafting technique described previously, we were able to rescue the prostates of Tgfr2^{fspKO} mice into both immunocompromised SCID and syngenic C57/Bl6 mice. Following seven months of xenografting, we found that the prostates of Tgfr2^{fspKO} mice had developed adenocarcinoma phenotype (**Figure 2**). The prostates of the control, Tgfr2^{floxE2/floxE2}, grafted under the same conditions maintained a normal phenotype.





Figure 2. The progression of tumorigenesis in $Tgfb2^{fspKO}$ prostates to adenocarcinoma.

The greater proliferative potential of the prostate mediated by the $Tgfb2^{fspKO}$ stromal cells is not unique to the TNT model

The original proposal suggested the genetic recombination of the loss of the $T\beta RII$ expression in the stromal compartment with the overexpression of the large T antigen in the epithelial compartment to be termed the TNT model (described in the previous report). However, manuscript reviewers suggested the need for other examples of the paracrine role for the stromal deletion of $Tgfb2$. we addressed this concern through the development of sub-renal capsule tissue recombination models of the $Tgfb2^{fspKO}$ prostatic stromal cells with the well established human prostate cancer cell line, LNCaP cells. the recombination of the LNCaP cells with $Tgfb2^{fspKO}$ stromal cells resulted in greater tumor size compared to when grafted with control, $Tgfb2^{floxE2/floxE2}$ stromal cells (n =12, **Figure 3A**). As the LNCaP cells are adenocarcinoma cells little histologic differences were observed between the association with either stromal cell type (**Figure 3B**). However, the greater tumor size was clearly a result of increased proliferation, as determined by phospho-histone3 immunohistochemical staining (**Figure 3B**). The $Tgfb2^{fspKO}$ associated tumors were also refractile to androgen ablation (data not shown).

A



B




Figure 3. The tissue recombination of LNCaP and prostatic stromal cells from $Tgfb2^{floxE2/floxE2}$ and $Tgfb2^{fspKO}$ mice. (A) Gross tumor size of recombinations associated with $Tgfb2^{fspKO}$ stromal cells was 5 times greater than those associated with $Tgfb2^{floxE2/floxE2}$ cells. (B) The histology of the tumors were not significantly different, however the proliferation rate was significantly greater, based on the counting phosphorylated-histone 3 positive cells in 20 high power fields - mean indicated in the right corner.

TGF- β in the prostatic stroma

which the tumorigenic phenomena observed in ografts. In the previous report, we described the cells from $Tgfr2^{fspKO}$ mice. The neutralization of TGF- β was able to reverse the androgen independence of the LNCaP cells. In the subsequent studies, Wnt3a expression was consistently up regulated close to 10 fold in those from $Tgfr2^{floxE2/floxE2}$ mice (**Figure 4A**). $Tgfr2^{fspKO}$ prostatic stromal cells, although to a lesser extent, also promoted tumor growth. This was initially done *in vitro*, where LNCaP cells were cultured in the presence of conditioned media from $Tgfr2^{fspKO}$ cells causing the cells to proliferate. A similar increase in cell number was observed as increasing concentrations of $Tgfr2^{fspKO}$ -conditioned media (**Figure 4B**). Cell proliferation following treatment with conditioned media with the over expression of Wnt3a by the $Tgfr2^{fspKO}$ stroma for increased prostatic growth in the presence

B




Figure 5. Wnt3a expression by $Tgfr2^{fspKO}$ prostatic stromal cells mediates greater tumor growth. (A) RNA from $Tgfr2^{floxE2/floxE2}$ and $Tgfr2^{fspKO}$ cells were subjected to realtime quantitative RT-PCR for seventeen Wnt ligand isoforms. (B) Conditioned media from $Tgfr2^{fspKO}$ stromal cells were placed on LNCaP cells in the absence and presence of an increasing concentration of Wnt3a neutralizing antibody. The LNCaP cells were counted following 72hs of incubation as a measure of proliferative measure of the cells.

Epithelial TGF- β responsiveness does not affect prostatic regression following androgen ablation

To study the role of TGF- β on the prostatic epithelia following androgen ablation, we developed a conditional $Tgfr2$ knockout by crossing NKX3.1-Cre mice with $Tgfr2^{floxE2/floxE2}$ mice¹, termed $Tgfr2^{NKX3.1KO}$. Crossing the $Tgfr2^{NKX3.1KO}$ mice further into the Rosa26 line enabled the immunohistochemical localization for β -galactosidase expression associated with recombination in the prostatic epithelia (**Figure 5A**). However, since $Tgfr2^{NKX3.1KO}$ mice died at birth, the prostatic development and androgen responsiveness could not be studied. Consequently, their urogenital sinuses were rescued by allografting into male syngeneic, C57/Bl6 mice. Six weeks following allografting to the sub-renal capsule, as above, the host mice were either left intact or

castrated. All grafts were harvested 7 weeks following allografting for histologic examination. Hematoxylin and eosin staining revealed little difference in the ductal structures of the $Tgfr2^{NKX3.1KO}$ prostates compared to $Tgfr2^{floxE2/floxE2}$ controls (**Figure 5B**). TUNEL staining of the allografts suggested greater apoptosis of $Tgfr2^{NKX3.1KO}$ prostates (both stromal and epithelial compartments) in the intact hosts compared to $Tgfr2^{floxE2/floxE2}$ allografts. In turn, observed greater epithelial proliferation by Ki67 staining in the $Tgfr2^{NKX3.1KO}$ prostates in intact host mice, was an indication of the elevated intrinsic turnover of $Tgfr2^{NKX3.1KO}$ prostates (data not shown). However, there was further elevation of prostatic epithelial TUNEL

staining of the $Tgfr2^{NKX3.1KO}$ prostates following castration, similar to $Tgfr2^{floxE2/floxE2}$ allografts (**Figure 5B**). Taken together, there was no apparent difference in prostatic apoptosis observed between $Tgfr2^{floxE2/floxE2}$ and $Tgfr2^{NKX3.1KO}$ prostates following castration.




Figure 5. Conditional knockout of *Tgfr2* in the prostatic epithelia, $Tgfr2^{NKX3.1KO}$, did not significantly affect the response to androgen ablation compared to control $Tgfr2^{floxE2/floxE2}$ prostates. **(A)** Immunohistochemistry for β -galactosidase expression in $Tgfr2^{NKX3.1KO}/Rosa26$ indicates Cre-recombination in the prostatic epithelia compared to control, $Tgfr2^{floxE2/floxE2}/Rosa26$ prostates with no detectible staining (brown). The stromal (S) and epithelial (E) compartments are indicated. **(B)** Hematoxylin and eosin staining of the upper panels suggest similar development of $Tgfr2^{NKX3.1KO}$ and $Tgfr2^{floxE2/floxE2}$ prostates (n=4). However, TUNEL staining in the lower panels indicate differential apoptosis of the prostatic epithelia of $Tgfr2^{NKX3.1KO}$ and $Tgfr2^{floxE2/floxE2}$ allografts in hosts that were not castrated (+Androgen) and castrated (-Androgen). The immunohistochemistry stained sections (A, B) were nuclear counterstained with hematoxylin (blue).

c. Significance: Surgery and androgen ablation therapy remains the major treatment for prostate cancer. However, within a year of treatment >80% of prostate cancer becomes androgen independent as a result of documented mutations in AR and unknown factors. New treatments are required that are more effective irrespective of the structure of the AR in the cancerous epithelial cells. Based on our analysis of the *Tgfr2^{fspko}* mouse model and human prostate cancer tissues, we believe that targeting therapy to the prostate stroma rather than the cancer cells may be prudent in patients' androgen non-responsive prostate cancer. The studies in the past year suggest that the specific treatment may be through the targeting of the Wnt3a signaling axis. The non-transformed stromal cells are likely to have greater genomic stability and are less likely to be subject of mutation adaptation since the target would be the secretion of paracrine factors that would act on the epithelia.

d. Plans: The primary experimental task would be to follow up the results presented with neutralizing antibody treatment of prostate tumors in mouse models *in vivo*. Preliminary data not shown suggest good tolerance of the neutralizing antibody in mice. We will be able to assess the impact of the Wnt3a neutralizing antibody on tumor size within 6 months. The other immediate goal is to have the two manuscripts currently in review to be finally published in high level journals. Finally, we would like to leverage the findings of this grant to apply for a NIH supported R01.

KEY RESEARCH ACCOMPLISHMENTS

- Identified for the first time, that human prostate cancer often has a loss of T β RII expression in the stromal compartment. The epithelial compartment, in contrast rarely loses T β RII expression except in foci of very high grade prostate cancer.
- We showed that Wnt3a is highly expressed by the prostatic stroma and that its neutralization can inhibit prostate cancer growth *in vitro*
- The loss of T β RII expression in the epithelial compartment does not significantly affect androgen responsiveness of the prostate.

REPORTABLE OUTCOMES

Research *Manuscripts*

Veronica R. Placencio, Ali-Reza Sharif-Afshar, Xiaohong Li, Hongxia Huang, Consolate Uwamariya, Eric G. Neilson, Michael M. Shen, Simon W. Hayward, Neil A. Bhowmick (2007) TGF- β responsiveness modulates paracrine prostatic sensitivity to androgen ablation. *In review*.

Xiaohong Li, Veronica R. Placencio, Juan Iturregui, Ali-Reza Afshar-Sharif, Neil A. Bhowmick (2007) Loss of TGF- β receptor expression in the prostatic stroma can promote tumorigenesis in men. *In review*

Abstracts

Veronica R. Placencio, Ali-Reza Sharif-Afshar, Xiaohong Li, Robert J. Matusik, Simon W. Hayward, Neil A. Bhowmick (2006) Wnt signaling contributes to the androgen independence of prostatic epithelia resulting from the loss of TGF- β responsiveness of the stroma. Annual Fall Meeting of the Society for Basic Urologic Research. Pheonix, AZ.

Awards received based on work supported by this grant

Invited speaker, Travel Award to the Annual Fall Meeting of the Society for Basic Urologic Research. Pheonix, AZ.

Products *CDNA construct, cell lines, and animal models developed*

The NKX3.1-Cre mice were crossed with Tgfb β 2^{floxE2/floxE2} mice to generate the Tgfb β 2^{NKX3.1KO} mouse model. The Tgfb β 2^{NKX3.1KO} mice were additionally crossed with Rosa26 mice to enable visualization of cells undergoing Cre-mediated recombination.

CONCLUSION

Our study demonstrates that stromal and epithelial responsiveness to TGF- β dictates androgen sensitivity in the epithelia of prostate glands. The mouse model with the TGF- β type II receptor conditionally knocked out in fibroblasts, Tgfb β 2^{fspKO}, also demonstrates the integral role of stromal TGF- β signaling during prostatic epithelial regression². The Tgfb β 2^{fspKO} stromal cells themselves acquired a more proliferative phenotype and promoted nearby epithelia to increase their rate of proliferation to overcome hormonal dependence. After castration of host mice, we found the prostatic ducts associated with Tgfb β 2^{fspKO} stromal cells were also refractile to androgen ablation. The direct role of TGF- β signaling on the prostatic epithelia *in vivo* was minimal based on histologic differences between the Tgfb β 2^{NKX3.1KO} and Tgfb β 2^{floxE2/floxE2} prostates. However, the Tgfb β 2^{NKX3.1KO} prostates had greater cell turnover compared to control in non-castrated hosts. The mechanisms behind the observed phenomena highlight a paracrine TGF- β signaling axis that is altered upon androgen ablation.

The differentiation of the prostatic epithelium and stroma occur concurrently in an androgen-dependent mechanism. The loss of stromal TGF- β responsivity can result in the development of adenocarcinoma in the mouse model with no other directed genetic alteration in the epithelial compartment. Coincidentally, human prostate cancer also has a loss of T β RII expression in the stromal compartment. To examine the mechanism of these observations, we found that stromally derived paracrine Wnt3a mediates prostate cancer epithelial growth.

REFERENCES

- Attisano, L., and Wrana, J. L. (2002). Signal transduction by the TGF-beta superfamily. *Science* 296, 1646-1647.
- Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., and Moses, H. L. (2004). TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science* 303, 848-851.
- Byrne, R. L., Leung, H., and Neal, D. E. (1996). Peptide growth factors in the prostate as mediators of stromal epithelial interaction. *Br J Urol* 77, 627-633.
- Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Hittmair, A., Zhang, J., Thurnher, M., Bartsch, G., and Klocker, H. (1996). Regulation of prostatic growth and function by peptide growth factors. *Prostate* 28, 392-405.
- Hayward, S. W., and Cunha, G. R. (2000). The prostate: development and physiology. *Radiol Clin North Am* 38, 1-14.
- Hayward, S. W., Haughney, P. C., Lopes, E. S., Danielpour, D., and Cunha, G. R. (1999). The rat prostatic epithelial cell line NRP-152 can differentiate in vivo in response to its stromal environment. *Prostate* 39, 205-212.
- Hayward, S. W., Haughney, P. C., Rosen, M. A., Greulich, K. M., Weier, H. U., Dahiya, R., and Cunha, G. R. (1998). Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. *Differentiation* 63, 131-140.
- Kasper, S., Sheppard, P. C., Yan, Y., Pettigrew, N., Borowsky, A. D., Prins, G. S., Dodd, J. G., Duckworth, M. L., and Matusik, R. J. (1998). Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. *Lab Invest* 78, i-xv.
- Kyprianou, N., and Isaacs, J. T. (1989). Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. *Mol Endocrinol* 3, 1515-1522.
- Martikainen, P., Kyprianou, N., and Isaacs, J. T. (1990). Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. *Endocrinology* 127, 2963-2968.
- Montgomery, J. S., Price, D. K., and Figg, W. D. (2001). The androgen receptor gene and its influence on the development and progression of prostate cancer. *J Pathol* 195, 138-146.